Patients on Eli Lilly's Mounjaro were more likely to lose weight and experienced larger reductions in body weight compared to those on Novo Nordisk's Ozempic.

The maker of weight-loss jabs Wegovy and Ozempic, Danish pharmaceutical giant Novo Nordisk, has reported a sharp rise in profits on the back of surging demand for the drugs. Net profits were 39.2bn kroner (£4.5bn) for the period from January to June, rising 43% from 27.5bn kroner a year earlier.

Mounjaro, which is the brand name for tirzepatide, was shown to be even more powerful than Ozempic in a recent study with adults who were overweight or obese.

In today’s fast-paced world, the pursuit of the perfect body has never been more prevalent. With the rise of social media and the constant barrage of fitness trends, it’s no wonder that people are always on the lookout for the next big thing in weight loss.